RECRUITING

Early PKD Observational Cohort Study

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This observational study will collect blood and urine and clinical information from individuals with early-stages of polycystic kidney disease (PKD), their unaffected siblings and normal volunteers to create a biobank, also called a biorepository. The long-term goal is to develop new knowledge on biological markers or biomarkers that indicate changes in the disease progression. An understanding of biomarkers for early renal cyst growth will benefit PKD patients as new therapies are being developed and tested.

Official Title

Early PKD Observational Cohort Study

Quick Facts

Study Start:2016-04
Study Completion:2025-06
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02936791

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:4 Years to 35 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT
Inclusion CriteriaExclusion Criteria
  1. * Inclusion for early stage autosomal dominant polycystic kidney disease (ADPKD):
  2. * Family history of PKD
  3. * All races and ethnic groups
  4. * Glomerular filtration rate (GFR) \>80 ml/min per 1.73 m2
  5. * Inclusion for Healthy Volunteers:
  6. * Male or female with no family history of kidney disease
  7. * All races and ethnic groups
  8. * Normal GFR
  1. * Non-insulin or insulin-dependent diabetes mellitus
  2. * Systemic illness (i.e.systemic lupus erythematosus, vasculitis)
  3. * Unable to provide written informed consent
  4. * Unavailable for magnetic resonance imaging (MRI) and blood/urine collection

Contacts and Locations

Study Contact

Cathy Creed, RN
CONTACT
913-588-0053
ccreed@kumc.edu

Principal Investigator

Alan SL Yu, MD
PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center
Darren P Wallace, PhD
PRINCIPAL_INVESTIGATOR
University of Kansas Medical Center

Study Locations (Sites)

University of Chicago
Chicago, Illinois, 60637
United States
University of Kansas Medical Center
Kansas City, Kansas, 66160
United States
Children's Mercy Hospital
Kansas City, Missouri, 64108
United States

Collaborators and Investigators

Sponsor: University of Kansas Medical Center

  • Alan SL Yu, MD, PRINCIPAL_INVESTIGATOR, University of Kansas Medical Center
  • Darren P Wallace, PhD, PRINCIPAL_INVESTIGATOR, University of Kansas Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2016-04
Study Completion Date2025-06

Study Record Updates

Study Start Date2016-04
Study Completion Date2025-06

Terms related to this study

Keywords Provided by Researchers

  • autosomal dominant polycystic kidney disease
  • ADPKD
  • PKD biomarkers
  • Kidney Institute
  • University of Kansas Medical Center

Additional Relevant MeSH Terms

  • Polycystic Kidney Disease